Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SRDX

DatePrice TargetRatingAnalyst
3/7/2025$43.00Hold → Buy
Lake Street
6/13/2023$36.00Hold → Buy
Needham
2/13/2023Buy → Hold
Needham
2/4/2022$70.00 → $58.00Buy
Needham
11/10/2021$76.00 → $70.00Buy
Needham
9/8/2021$68.00 → $76.00Buy
Needham
More analyst ratings

$SRDX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

    With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the fully mechanical Pounce™ Thrombectomy Platform can now remove thrombi or emboli throughout the lower and upper extremities without aspiration, thrombolysis, or capital equipment Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral arteries. Intended for removal of thrombi and emboli from pe

    $SRDX
    Medical/Dental Instruments
    Health Care
  • Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

    Surmodics, Inc. (NASDAQ:SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's ("FTC" or the "Agency") announcement that it will challenge the proposed acquisition of Surmodics (the "Merger") by funds affiliated with GTCR LLC ("GTCR"), which have an equity investment in Biocoat Inc., a maker of medical coatings: "Surmodics respectfully disagrees with the FTC's decision and remains committed to completing the Merger. Surmodics remains confident in both its rationale for the Merger and the value it will bring to all stakeholders, including shareholders, cust

    $SRDX
    Medical/Dental Instruments
    Health Care
  • Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

    With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the Pounce™ Thrombectomy Platform can now rapidly remove acute or chronic clot throughout the lower extremity without aspiration, thrombolysis, or capital equipment. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch pl

    $SRDX
    Medical/Dental Instruments
    Health Care

$SRDX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SRDX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SRDX
SEC Filings

See more

$SRDX
Leadership Updates

Live Leadership Updates

See more
  • KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

    $KRMD
    $SRDX
    Medical/Dental Instruments
    Health Care

$SRDX
Financials

Live finance-specific insights

See more
  • Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

    $SRDX
    Medical/Dental Instruments
    Health Care
  • Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $31.3 million, an increase of 17% year-over-year GAAP net loss of $(3.4) million, compared to net income of $6.7 million in the prior-year period Adjusted EBITDA(2) of $4.4 million, compared to $1.7 million in the prior-year period Fiscal 2024 Financial Summa

    $SRDX
    Medical/Dental Instruments
    Health Care
  • Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of $30.3 million, compared to $52.5 million in the prior-year period which included $24.6 million in license fee revenue recognized upon receipt of a $27.0 million milestone payment associated with obtaining FDA premarket approval of the SurVeil™ drug-coated balloon ("DCB") Total Revenue excluding SurVeil DCB license fee revenue(1) of $29.2 million, an increase of 10% year-over-year GAAP net loss of $(7.6) million, co

    $SRDX
    Medical/Dental Instruments
    Health Care

$SRDX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more